The Clinical Efficacy of Plendil and Jiangzhiruanmai Tablets in Patients with Essential Hypertension

Objective To assess the antihypertensive effect,symptom,safety and insulin resistance of felodipine sustained release tablets and jiangzhiruanmai tablets in treatment of essential hypertension(EH) for four weeks and to investigate the relationship between the hypertensive and obesity patients and insulin resistance(IR).Methods An open-labeled study was conducted.Thirty patients in sixty with systolic blood pressure(SBP) were treated with felodipine sustained release tablets and Jiangzhiruanmai tablests the dosage of felodipine sustained release tablets was one tablet(2.5 mg) per day,and the dosage of jiangzhiruanmai tablets was six tablets per time,three times per day.Other thirty patieny patients were only treated with felodipine sustained release tablests,the dosage was 2.5 mg per day.The antihypertensive effect and symptom effect and IR'S effect were observed.Results Compare with the baseline afterward,the SBP and DBP of treatment group and control group singificantly decreased after taking medicines.The antihypertensive peak of two group is after on week.Significant difference was found between treatment group and control HOMA-IR in the obesity group is higher than those in normal body weight group and significant difference was found(p0.05,p0.01)Conclusion(1)Felodipine sustained release tablets and Jiangzhiruanmai tablets in treatment of hypertension is better than only felodipine sustained release tablets,especially in the improve of symptom.Jiangzhiruanmai tablets has remarkable advantage in improving symptom of patients with hypertension.(2) The obesity is one of factors in inducing HOMA-IR with EH.